Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Type 2 diabetes remission one year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

This post hoc analysis investigated effects of insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers from DUAL II (versus insulin degludec), DUAL V (versus insulin glargine 100 units/mL) and DUAL VII (versus basal-bolus therapy) in patients grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years). Treatment contrasts were in favour of IDegLira in many subgroups for changes from baseline in HbA1c (DUAL II, DUAL V), body weight (all three trials), systolic blood pressure (BP; all three trials), high-density lipoprotein cholesterol (DUAL VII) and low-density lipoprotein cholesterol (LDL-C; DUAL II, DUAL V). Higher heart rates were seen with IDegLira versus comparators (all three trials) plus significantly higher diastolic BP in males (DUAL V). Differences in treatment effect were seen between sexes in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL-C (DUAL V). In conclusion, IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal-bolus therapy after 26 weeks of treatment. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftDiabetes, Obesity and Metabolism
Vol/bind21
Udgave nummer6
Sider (fra-til)1506-1512
Antal sider7
ISSN1462-8902
DOI
StatusUdgivet - jun. 2019

ID: 56671202